Treatment of Advanced Melanoma With MK-3475 and Peginterferon
Phase 1 Study of Anti-PD-1 Antibody MK-3475 and Peginterferon Alfa-2b for Advanced Melanoma
Sponsor: Hassane M. Zarour, MD
Listed as NCT02112032, this PHASE1 trial focuses on Melanoma and remains completed. Sponsored by Hassane M. Zarour, MD, it has been updated 13 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2021 — Jun 2022 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 8 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE1
-
Sep 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Nov 2018 — Sep 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Nov 2018 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE1
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Sep 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hassane M. Zarour, MD
- Melanoma Research Alliance
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .